公开(公告)号：EP1534313B1

公开(公告)日：2012-10-17

申请号：EP03772122.2

申请日：2003-07-30

申请人： Omeros Corporation

发明人： DEMOPULOS, Gregory, A. ,  PALMER, Pamela, Pierce ,  HERZ, Jeffrey, M.

IPC分类号： A61K31/00 ,  A61K45/06 ,  A61K9/00 ,  A61K38/00

CPC分类号： A61K31/573 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/00 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/4409 ,  A61K31/445 ,  A61K31/5377 ,  A61K45/06

公开(公告)号：EP1496835A2

公开(公告)日：2005-01-19

申请号：EP03708941.4

申请日：2003-01-31

申请人： Omeros Corporation

发明人： DEMOPULOS, Gregory, A. ,  PALMER, Pamela, Pierce ,  HERZ, Jeffrey, M.

IPC分类号： A61K6/00

CPC分类号： B82Y5/00 ,  A61K47/6849 ,  A61K47/6929 ,  A61K47/6935 ,  A61K47/6937

摘要： Methods and compositions for inhibiting articular cartilage degradation. The compositions preferably include multiple chondroprotective agents, including at least one agent that promotes cartilage anabolic activity and at least one agent that inhibits cartilage catabolism. The compositions may also include one or more pain and inflammation inhibitory agents. The compositions may be administered systemically, such as to treat patients at risk of cartilage degradation at multiple joints, and suitably may be formulated in a carrier or delivery vehicle that is targeted to the joints. Alternatively the compositions may be injected or infused directly into the joint.

公开(公告)号：EP1406629A1

公开(公告)日：2004-04-14

申请号：EP02721261.2

申请日：2002-02-28

申请人： Omeros Corporation ,  The Regents of The University of California

发明人： DEMOPULOS, Gregory, A. ,  PALMER, Pamela, Pierce

IPC分类号： A61K31/485 ,  A61K31/4468 ,  A61K31/4535 ,  A61K31/454 ,  A61K38/07 ,  A61M5/142

CPC分类号： A61M5/14276 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4468 ,  A61K31/4535 ,  A61K31/485 ,  A61K38/07 ,  A61K38/08 ,  A61K38/10 ,  A61M5/16827 ,  A61M5/16877 ,  A61M2202/048 ,  A61M2205/3523

摘要： A method of producing analgesia in a mammal is provided by rotational (alternating) intrathecal administration to the mammal of a pharmaceutically effective dose of at least one opioid receptor agonist, such as a ν-, δ- or λ-opioid receptor agonist for a first period of time, followed by intrathecal administration to the mammal of a pharmaceutically effective dose of at least one opioid receptor-like receptor 1 (ORL-1) agonist for a second period of time. The intrathecal drug administration of the first and second periods of time may be repeated a plurality of times without attaining tolerance in the mammal to either drug. Implantable apparatus for rotational administration of the active agents is also disclosed.

公开(公告)号：EP1567179A1

公开(公告)日：2005-08-31

申请号：EP02793939.6

申请日：2002-11-12

申请人： Omeros Corporation

发明人： DEMOPULOS, Gregory, A. ,  PALMER, Pamela, Pierce ,  HERZ, Jeffrey, M. ,  TANELIAN, Darrell

IPC分类号： A61K38/00 ,  A61K31/70 ,  A61K31/55 ,  A61K31/54 ,  A61K31/495 ,  A61K31/505 ,  A61K39/395 ,  A61K39/00

CPC分类号： A61K45/06 ,  A61K31/495 ,  A61K31/505 ,  A61K31/54 ,  A61K31/55 ,  A61K31/70 ,  A61K38/06 ,  A61K38/08 ,  A61K38/177 ,  A61K38/178 ,  A61K2300/00

摘要： A method and solution for perioperatively inhibiting tumor cell adhesion and a variety of pain and inflammation processes at wounds from general surgical procedures including oral/dental procedures. The solution preferably includes at least one anti-tumor cell adhesion agent and multiple pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for preemptive inhibition of pain and while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit tumor cell adhesion, pain and inflammation includes at least one anti-tumor cell adhesion agent, a serotonin2 antagonist, a serotonin3 antagonist, a histamine antagonist, a serotonin agonist, a cyclooxygenase inhibitor, a neurokininl antagonist, a neurokinin2 antagonist, a purinoceptor antagonist, an ATP-sensitive potassium channel opener, a calcium channel antagonist, a bradykininl antagonist, a bradykinin2 antagonist and a ν-opioid agonist.

公开(公告)号：EP1534313A2

公开(公告)日：2005-06-01

申请号：EP03772122.2

申请日：2003-07-30

申请人： Omeros Corporation

发明人： DEMOPULOS, Gregory, A. ,  PALMER, Pamela, Pierce ,  HERZ, Jeffrey, M.

IPC分类号： A61K38/00 ,  A61K31/56 ,  A61K31/19

CPC分类号： A61K31/573 ,  A61K9/0048 ,  A61K9/08 ,  A61K31/00 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/4409 ,  A61K31/445 ,  A61K31/5377 ,  A61K45/06

摘要： Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.